Johnson & Johnson and Realty Income are recommended as long-term dividend stocks. J&J, a Dividend King with 64 consecutive years of dividend increases, offers defensive healthcare stability through its innovative medicine and medtech businesses. Realty Income, with 136 monthly dividend increases, provides predictable income through its diversified commercial real estate portfolio with strong occupancy and expansion into data centers and private capital partnerships.

In a comparison of two Consumer Products - Staples sector stocks, Newell Brands (NWL) emerges as the superior value investment option compared to Kenvue (KVUE). NWL holds a Zacks Rank #1 (Strong Buy) with a forward P/E of 7.21 and Value grade of A, while KVUE has a Zacks Rank #4 (Sell) with a forward P/E of 15.22 and Value grade of C. NWL's improving earnings outlook and stronger valuation metrics make it the more attractive choice for value investors.

Kenvue (KVUE) is highlighted as a smart high-yield dividend stock with a 4.68% dividend yield and 64 consecutive years of dividend increases, making it a Dividend King. The company, spun off from Johnson & Johnson three years ago, generates steady revenue from recession-resilient consumer healthcare brands like Tylenol and Neutrogena. However, uncertainty exists due to a pending acquisition by Kimberly-Clark (KMB), another Dividend King with a 5.23% yield.

Kimberly Clark, a Dividend King with an attractive 5% yield, has fallen 20% from its 52-week high. However, the company faces significant headwinds including lowered full-year guidance, a major acquisition of Kenvue that will increase leverage, high dividend payout ratio of 85%, and underperformance compared to better-run competitors like Procter & Gamble. Only aggressive dividend investors should consider buying at current levels.

Kenvue has secured shareholder approval and U.S. antitrust clearance for its planned Q4 2026 combination with Kimberly-Clark. However, the deal faces ongoing risks including weak Self Care segment performance, $8.5B debt burden, margin pressures from inflation and tariffs, restructuring costs, and pending litigation. Q2 results showed 3% sales growth but EPS missed estimates with adjusted gross margin declining 70 basis points.

Kenvue Inc. (KVUE) demonstrated improved profitability in the first half of 2026, with adjusted operating margins rising 180 basis points to 23.1% and earnings climbing 18.9%, driven primarily by cost-cutting initiatives. However, organic sales growth remained modest at 1.2%, with the Self Care segment struggling while Skin Health and Beauty showed stronger performance. The company faces headwinds from tariffs, inflation, and $8.5 billion in debt, with a pending merger with Kimberly-Clark expected to close in Q4 2026.

The global skin care products market is projected to grow from USD 166 billion in 2025 to USD 262 billion by 2034, with a CAGR of approximately 5%. Growth is driven by rising consumer awareness of skin health, increasing disposable incomes, demand for premium and personalized products, and the influence of social media trends. Asia-Pacific leads with 38% market share, while North America is the fastest-growing region. Key players include L'Oréal, Unilever, Procter & Gamble, and Estée Lauder.

Kimberly-Clark is an overlooked Dividend King with a 54-year consecutive dividend increase streak matching PepsiCo's. Despite lower brand recognition, KMB offers a higher yield (4.7% vs 4.1%), more resilient demand for household products, and is acquiring Kenvue to enhance its global portfolio, making it an attractive option for income-focused investors.

Johnson & Johnson and AbbVie are recommended as long-term dividend stocks to hold indefinitely. Both are Dividend Kings with strong cash flows, reliable dividend payments, and solid historical returns. JNJ has increased dividends for 64 consecutive years with a 1.96% yield, while ABBV has 54 years of increases with a higher 2.6% yield and stronger recent performance.

Johnson & Johnson is transitioning from a slow-growth dividend stock into a growth machine, driven primarily by its oncology business. The company's cancer drugs, particularly Darzalex, are growing at high-teen rates, positioning J&J to achieve its goal of $50 billion in annual cancer drug sales by 2030. With the global cancer treatment market expected to grow at 11.3% annually through 2035, J&J is well-positioned to capture significant market share despite being primarily viewed as an income investment.

Johnson & Johnson delivered strong earnings with revenue growth of 6% to $25 billion and raised full-year guidance to $101.1 billion. Key drugs like Darzalex (up 18%) and Tremfya (up 72%) offset Stelara declines. While the stock has gained 22% this year and trades near valuation highs, the company's broad portfolio of 28+ blockbuster products and 50+ years of dividend increases make it attractive for long-term and dividend-focused investors, though value investors may wait for a better entry point.

Ken Griffin increased his stake in Johnson & Johnson by 146% in Q1 2026, bringing his total holdings to nearly 2 million shares. The article highlights J&J as an ideal stock for risk-averse investors due to its diversified portfolio of 28+ billion-dollar products, strong revenue growth in pharmaceuticals and medtech following the Kenvue spinoff, and its status as a Dividend King with 50+ consecutive years of dividend increases and a 2% yield.